The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global metabolomics market reached a value of US$ 2.1 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 4.2 Billion by 2027, exhibiting a CAGR of 12% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Metabolomics refers to the large-scale study of metabolites, or small molecules, in cells, biofluids, tissues and organisms. It is an analytical approach for systematic metabolic profiling and fingerprinting in various biological samples and systems. It consists of various detection techniques, such as nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry (MS), along with separation techniques, such as gas chromatography. These techniques are commonly used for metabolome studies, toxicology testing and developing personalized medicine. They also provide an assessment of health and an insight into the causes and treatment of medical ailments, such as cardiovascular and neurological diseases and cancer.
The increasing prevalence of cancer and other chronic diseases is one of the key factors driving the growth of the market. Furthermore, a significant increase in the pharmaceutical industry, along with the rising demand for personalized medicines, is also providing a boost to the market growth. Metabolomics facilitates the study of genes and proteins, along with the development of biomarkers that aid in the discovery and development of medicines and managing disease progression. Additionally, the integration of metabolomics with machine learning (ML) is also favoring the market growth. ML aids in the accurate interpretation of data generated using the NMR and MS techniques and automates complex, repetitive and time-consuming processes. Advanced ML software also offers comprehensive analysis and visualization functions for the representation of large amounts of data. Other factors, including rapid urbanization and extensive research and development (R&D) activities in the field of biotechnology, are projected to drive the market in the upcoming years.
IMARC Group provides an analysis of the key trends in each sub-segment of the global metabolomics market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product, indication and application.
Breakup by Product:
Breakup by Indication:
Breakup by Application:
Breakup by Region:
The competitive landscape of the industry has also been examined with some of the key players being Agilent Technologies Inc., Biocrates Life Sciences AG, Bio-Rad Laboratories Inc., Bruker Corporation, Danaher Corporation, Human Metabolome Technologies Inc., Metabolon Inc., Shimadzu Corporation, Thermo Fisher Scientific Inc. and Waters Corporation, etc.
|Base Year of the Analysis||2021|
|Segment Coverage||Product, Indication, Application, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Agilent Technologies Inc., Biocrates Life Sciences AG, Bio-Rad Laboratories Inc., Bruker Corporation, Danaher Corporation, Human Metabolome Technologies Inc., Metabolon Inc., Shimadzu Corporation, Thermo Fisher Scientific Inc. and Waters Corporation|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at